News & Updates

Show Multimedia Only

Olpasiran reduces oxidized phospholipids but not inflammatory markers

24 Feb 2025

Treatment with olpasiran appears to induce a sustained and significant decrease in oxidized phospholipids associated with apolipoprotein B (OxPL-apoB) but exert no substantial effect on high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity interleukin-6 (hs-IL-6), according to data from the phase II, dose-finding OCEAN(a)-DOSE trial.

Olpasiran reduces oxidized phospholipids but not inflammatory markers

24 Feb 2025

Long-term colchicine use helps prevent stroke, cardiac events

23 Feb 2025 by

Treatment with colchicine appears to lower the risk of stroke and major adverse cardiovascular events (MACE) when used for longer duration, according to a study presented at ISC 2025. This beneficial effect, however, is not observed among patients with shorter follow-up duration.

Long-term colchicine use helps prevent stroke, cardiac events

23 Feb 2025

Experimental drug for PD well-tolerated, offers cognitive benefits

22 Feb 2025

In the treatment of patients with Parkinson’s disease (PD), the muscarinic acetylcholine M1 positive allosteric modulator TAK-071 falls short of improving gait, according to the results of a phase II study. However, the drug appears to be well-tolerated and have positive effect on cognition.

Experimental drug for PD well-tolerated, offers cognitive benefits

22 Feb 2025

Beta-blockers as first antihypertensives tied to more cardiac events

21 Feb 2025

Initiating antihypertensive treatment with an angiotensin-converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), or a calcium channel blocker (CCB) results in a comparable risk for myocardial infarction (MI), acute coronary syndrome (ACS), heart failure (HF), or stroke when compared with thiazides, reports a study. On the other hand, use of beta-blockers (BBs) tends to increase such risk.

Beta-blockers as first antihypertensives tied to more cardiac events

21 Feb 2025

Baloxavir shows promise in patients with nonsevere influenza

20 Feb 2025

In the treatment of patients with nonsevere influenza virus infection, baloxavir may reduce the risk of hospital admission and shorten the time to symptom relief, according to the results of a systematic review and meta-analysis.

Baloxavir shows promise in patients with nonsevere influenza

20 Feb 2025

Neoadjuvant docetaxel, radiotherapy feasible in high-risk prostate cancer

20 Feb 2025

Neoadjuvant radiation therapy and docetaxel prior to prostatectomy in men with localized high-risk prostate cancer has a modest toxicity profile and results in reasonable long-term outcomes, but pathologic complete response (pCR) is not achieved, results of a phase I/II trial have shown.

Neoadjuvant docetaxel, radiotherapy feasible in high-risk prostate cancer

20 Feb 2025

Postpartum diuretics use eases persistent hypertension

20 Feb 2025 by

The postpartum use of diuretics can reduce persistent hypertension in women with hypertensive disorders of pregnancy (HDP), according to the results of a systematic review and meta-analysis presented at SMFM 2025.

Postpartum diuretics use eases persistent hypertension

20 Feb 2025

MC4R agonist for obesity in young children scores high in phase III trial

20 Feb 2025

The melanocortin-4 receptor (MC4R) agonist setmelanotide demonstrates efficacy in the management of obesity in children younger than 6 years, according to the results of a phase III trial.